Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends reimbursement for Translarna
19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy. ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 19 Jan 2023
Drugs added to reimbursement list
19 January 2023 - China will add 111 drugs to its national medical reimbursement list this year, with a focus ...
Posted by Michael Wonder on 19 Jan 2023
Innovent announces inclusion in the China National Reimbursement Drug List of Tyvyt in two new indications, olverembatinib for the first listing, Byvadsa, Halpryza and Sulinno in multiple new indications
18 January 2023 - Innovent Biologics today announced that, five products (including new indications) of the company have been included in ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends all oral triplet regimen for patients living with relapsed or refractory multiple myeloma
19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has ...
Posted by Michael Wonder on 19 Jan 2023
Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of Tascenso ODT (fingolimod)
17 January 2023 - Tascenso ODT is now approved by the US FDA as a bioequivalent to Gilenya (fingolimod hydrochloride), for ...
Posted by Michael Wonder on 19 Jan 2023
Evaxion receives FDA fast track designation for personalised cancer immunotherapy
19 January 2023 - Evaxion Biotech today announced that the US FDA has granted fast track designation for the Company’s ...
Posted by Michael Wonder on 19 Jan 2023
Synlogic receives rare paediatric disease designation from FDA for SYNB1934 for phenylketonuria
19 January 2023 - Synlogic today announced that SYNB1934 was granted rare paediatric disease designation by the US FDA for the ...
Posted by Michael Wonder on 19 Jan 2023
FDA accepts Intercept’s new drug application for OCA for the treatment of pre-cirrhotic liver fibrosis due to NASH
19 January 2023 - PDUFA target action date set for 22 June 2023. ...
Posted by Michael Wonder on 19 Jan 2023
Abbott receives FDA approval for Navitor, a next generation TAVI system designed to treat aortic stenosis
17 January 2023 - Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood ...
Posted by Michael Wonder on 19 Jan 2023
FDA grants rare paediatric disease status to GC Pharma’s San Filippo syndrome therapy
18 January 2023 - GC Pharma said on Wednesday that its San Filippo Syndrome type A treatment, jointly being developed ...
Posted by Michael Wonder on 19 Jan 2023
Health Canada accepts nirsevimab regulatory submission for infant RSV
18 January 2023 - Nirsevimab is the first investigational long-acting antibody designed for all infants to help protect against respiratory syncytial ...
Posted by Michael Wonder on 18 Jan 2023
Zai Lab announces inclusion of Qinlock (ripretinib) and Nuzyra (omadacycline) in China’s National Reimbursement Drug List
18 January 2023 - Zai Lab today announced that the National Reimbursement Drug List released by China’s National Healthcare Security Administration ...
Posted by Michael Wonder on 18 Jan 2023
HUTCHMED announces agreement with NHSA for inclusion of Orpathys in the National Reimbursement Drug List in China
18 January 2023 - HUTCHMED China today announces, following negotiations with the China National Healthcare Security Administration, Orpathys (savolitinib) has been ...
Posted by Michael Wonder on 18 Jan 2023
BeiGene announces expansion of coverage on China’s National Reimbursement Drug List
18 January 2023 - Four new indications added for tislelizumab and all nine approved indications now included in National Reimbursement Drug List. ...